Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione
Patent No. EP3756650 (titled "Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione") was filed by Amgen Europe on Dec 26, 2012. The application was issued on Aug 20, 2025.
Patent Summary
Pharmaceutical compositions comprising (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione (Compound A) for treating various diseases and disorders, including cancer, pain, inflammatory diseases, and ocular neovascular diseases. The compositions comprise Compound A in combination with fillers, disintegrants, and lubricants, and may be formulated as tablets or capsules. The compositions exhibit advantageous physical and pharmacological properties, including fast disintegration, low friability, and stability.
Patent Family
Patent Oppositions (4)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3756650
- Application Number
- EP20172615A
- Filing Date
- Dec 26, 2012
- Status
- Granted And Under Opposition
- Jul 18, 2025
- Publication Date
- Aug 20, 2025
- External Links
- Slate, Register , Google Patents